As much as 2 analysts have advised buy on Novo Nordisk A/S (ADR) (NYSE:NVO) with an average broker rating of 2. Research Analysts at Zacks has the counter a rating of 3, which implies that the firms recommendation is Neutral on the company.
Major Brokerage house, Commerbank downgrades its ratings on Novo Nordisk A/S (ADR) (NYSE:NVO). According to the latest information available, the shares are now rated Hold by the analysts at the agency.
Merck & Co., Inc. (NYSE:MRK) and Novo Nordisk A/S (ADR) (NYSE:NVO) became the latest pharmaceutical companies to join the GPCR Consortium, which is working to explore the biology of proteins called G-protein coupled receptors.
The injectable drug is the second obesity treatment to be approved by the FDA this year; the first obesity-related treatment, approved in September, was Contrave, an oral medicine by Orexigen Therapeutics Inc. (NASDAQ:OREX).